Navigation Links
PTC Therapeutics Announces Drug Discovery Collaboration With Roche
Date:9/2/2009

iance is part of our ongoing strategy to leverage the broad value of the GEMS technology beyond our core research areas. Together with Roche, we are well-positioned to pursue high-interest targets to address complex CNS disorders and bring therapeutic options for patients in need."

About GEMS(TM)

GEMS is PTC's novel and proprietary technology platform for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology target processes that act through the regulatory regions of messenger RNA molecules. PTC has successfully employed the GEMS technology in drug discovery programs in oncology, infectious diseases, cardiovascular diseases and neuromuscular disorders. The most advanced compound identified through the GEMS technology is PTC299, a small-molecule inhibitor of VEGF expression currently in Phase 2 clinical trials for oncology.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. PTC has extensive knowledge of post-transcriptional control processes and has developed proprietary technologies that it applies in its drug discovery activities. PTC's expertise has been the basis for collaborations with leading biopharmaceutical companies such as Genzyme, Celgene, Pfizer, Gilead, Roche and Schering-Plough. For more information, visit the company's Web site at www.ptcbio.c
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015 Agricultural firm H.J. ... of its acquisition of Tiger-Sul. Since the purchase ... Alberta, Canada) in May 2005, H.J. Baker has leveraged ... it into a comprehensive portfolio of product offerings and ... H.J. Baker and the innovation of Tiger-Sul, transforming the ...
(Date:5/20/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at The Jefferies 2015 Global Healthcare Conference in ... st , 2015 at 8:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jeff88/hae ... is a global healthcare company dedicated to providing innovative ...
(Date:5/20/2015)... SEATTLE , May 20, 2015  Resolution Bioscience ... of ctDx ALK TM , a blood-based liquid ... non-small cell lung carcinoma (NSCLC), the most common form ... the test to guide patients to personalized therapies and ... sample. The Department of Health, the CLIA ...
(Date:5/20/2015)... Carolina , 20. Mai 2015 ... für klinische Logistik (Clinical Logistics Organization/CLO) ... Geschäftsjahr 2014, das am 31. Dezember ... Unternehmen hat die Marktentwicklung übertroffen und ... - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
Breaking Biology Technology:Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2
... Selexis SA , a global life science company with ... manufacturing of therapeutic proteins announced today that CSL Limited (ASX:CSL ... the preclinical development of a therapeutic antibody anticipated ... This commercial license agreement provides CSL with the rights to ...
... GERRARDS CROSS, England, July 26, 2011 , ... Sankyo, one of the,world,s top 20 pharmaceutical companies, ... system with Veeva,CRM in the UK. Daiichi Sankyo ... teams in the UK including integrated healthcare,specialty care, ...
... event at the University City Science Center in Philadelphia, ... Fattah (D-PA), Allyson Schwartz (D-PA) and Pat Meehan (R-PA) ... incentives for small and mid-sized businesses to invest in ... The Life Sciences Jobs and Investment Act of ...
Cached Biology Technology:CSL Limited Signs Commercial License Agreement with Selexis SA 2Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 2Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 3Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 4Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 2Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 3Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 4Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 5
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/21/2015)... , April 21, 2015 ... evolving government policies are boosting access control systems market ... According to a recently published report by TechSci ... 2020 ", the access control systems market in ... USD1.2 billion by 2020.The access control systems market in ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 2008The 2008 American Society for Microbiology (ASM) ... being presented to Adrian M. Zelazny, Staff ... National Institutes of Health (NIH). This award ... or antimicrobial therapy. Dr. Zelazny is ...
... 14, 2008) EPA has released the final "Integrated Science ... EPA,s latest evaluation of the scientific literature on the ... oxides of nitrogen, particularly nitrogen dioxide or NO2. ... since the last scientific review document released in 1993. ...
... in Spanish . Cancer is a ... adaptative changes give higher proliferative capacity to cancer cells, ... agents. The research group led by Dr. Jos Carlos ... the CSIC (IIBB-CSIC), a centre linked to the Institut ...
Cached Biology News:Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer 2
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Biology Products: